Clinical Trial

An Open-label Extension Safety and Efficacy Study of QCZ484 in Hypertensive Patients.

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this extension study is to collect additional safety and efficacy on QCZ484 for hypertensive patients who successfully completed the parent study, CQCZ484A12201 or additional QCZ484 studies as specified in the respective parent study protocols.
Protocol Amendment History 4 changes
notable Trial sites expanded: 13 -> 25 locations 2026-07-31
notable Trial sites expanded: 7 -> 13 locations 2026-07-02
critical Recruitment opened 2026-06-02
notable Trial sites expanded: 0 -> 7 locations 2026-06-02
Trial Details
NCT Number NCT07543120
Lead Sponsor Novartis Pharmaceuticals
Conditions Hypertension (HTN)
Enrollment 323 participants
Start Date 2026-05-07
Primary Completion 2031-05-31 (estimated)
Study Completion 2031-11-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-30